 SAN DIEGO, Aug. 25, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will be presented at the upcoming European Society for Medical Oncology Congress ESMO 2021, reinforcing the clinical benefit of adagrasib, a KRASG12C inhibitor, and sitravatinib, a receptor tyrosine kinase inhibitor. The congress will take place virtually from September 16 to 21, 2021. 